Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavituximab in HER2-Negative Metastatic Breast Cancer
NCT02651610Phase 3Withdrawn
- Sponsor
- Avid Bioservices, Inc.
- Start
- Dec 2015
- Primary completion
- Dec 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bavituximab in breast cancer, sponsored by Avid Bioservices, Inc.. Planned start Dec 2015; status: withdrawn.
02
Drugs
bavituximab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02651610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651610.